From: The pro-inflammatory potential of T cells in juvenile-onset systemic lupus erythematosus
Demographics | Juvenile-onset SLE patients (n = 30) |
---|---|
Number (%) female | 22 (73%) |
Ethnicity, number | |
White British | 22 |
White other | 1 |
Asian | 7 |
Age at sampling, mean (range) years | 12.4 (3.4 – 17.9) |
Disease duration, mean (range) years | 2.9 (0.01 – 10.2) |
Biomarker/disease activity parameter, mean (range) | |
ESR, mm/hour (normal 2 – 8 mm/hour) | 9.3 (<1 – 60) |
CRP, mg/litre (normal 0 – 8 mg/litre) | 6.8 (<4 – 78) |
C3, gm/litre (normal 1.1 – 1.9) | 1.03 (0.4 – 1.37) |
C4, gm/litre (normal 0.19 – 0.56) | 0.20 (0.08 – 0.46) |
Anti-dsDNA titre, IU/ml (normal <7) | 7.6 (0 – 96) |
C-HAQ score, 0–3, mean (range) | 0.32 (0 – 1.5) |
Physician’s global assessment of disease activity by VAS, mean (range) mm | 20 (0 – 75) |
SLEDAI score, mean (range) | 4.4 (0 – 17) |
BILAG-2004 | |
Number with grade A or grade B | 9 |
Score, mean (range) | 2.03 (0 – 8) |
Current medications number of patients | |
Hydroxychloroquine | 23 |
Methotrexate | 3 |
Azathioprine | 7 |
Mycophenolate mofetil | 12 |
Prednisolone | 13 |
Prednisolone dosage, mean (range) mg/day | 12.2 (1 – 40) |
Rituximab | 4 |